Maike Becker

Maike Becker

Auto-generated profile, based on publicly available information

Maike Becker

Research Unit Type 1 Diabetes Immunology, Helmholtz Diabetes Center at Helmholtz Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Cell Metabolism
Verified
Journal Article
Closed access
SKStefanie Kälin
Stefanie Kälin
MBMaike Becker
Maike Becker
VOVerena B. Ott
Verena B. Ott
ISIsabelle Serr
Isabelle Serr
FHFabian Hosp
Fabian Hosp
CDCarolin Daniel
Carolin Daniel

3 January 2018 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
ISIsabelle Serr
Isabelle Serr
MSMartin G. Scherm
Martin G. Scherm
AZAdam M. Zahm
Adam M. Zahm
JSJonathan Schug
Jonathan Schug
VFVictoria K. Flynn
Victoria K. Flynn
CDCarolin Daniel
Carolin Daniel
Molecular checkpoints that trigger the onset of islet autoimmunity or progression to human type 1 diabetes (T1D) are incompletely understood. Using T cells from children at an early stage of islet autoimmunity without clinical T1D, we find that a microRNA181a (miRNA181a)–mediated increase in signal strength of stimulation and costimulation links nuclear factor of activated T cells 5 (NFAT5) with impaired tolerance induction and autoimmune activation. We show that enhancing miRNA181a activity increases NFAT5 expression while inhibiting FOXP3+ regulatory T cell (Treg) induction in vitro. Accordingly, Treg induction is improved using T cells from NFAT5 knockout (NFAT5ko) animals, whereas altering miRNA181a activity does not affect Treg induction in NFAT5ko T cells. Moreover, high costimulatory signals result in phosphoinositide 3-kinase (PI3K)–mediated NFAT5, which interferes with FoxP3+ Treg induction. Blocking miRNA181a or NFAT5 increases Treg induction in murine and humanized models and reduces murine islet autoimmunity in vivo. These findings suggest targeting miRNA181a and/or NFAT5 signaling for the development of innovative personalized medicines to limit islet autoimmunity.

20 September 2017 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MBMaike Becker
Maike Becker
MLMegan K. Levings
Megan K. Levings
CDCarolin Daniel
Carolin Daniel

24 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JGJulia Geppert
Julia Geppert
AWAlina A. Walth
Alina A. Walth
RERaúl Terrón Expósito
Raúl Terrón Expósito
DKDoris Kaltenecker
Doris Kaltenecker
PMPauline Morigny
Pauline Morigny
MRMaria Rohm
Maria Rohm
Background: Cancer is primarily a disease of high age in humans, yet most mouse studies on cancer cachexia are conducted using young adolescent mice. Given that metabolism and muscle function change with age, we hypothesized that aging may affect cachexia progression in mouse models. Methods: We compare tumor and cachexia development in young and old mice of three different strains (C57BL/6J, C57BL/6N, BALB/c) and with two different tumor cell lines (Lewis Lung Cancer, Colon26). Tumor size, body and organ weights, fiber cross-sectional area, circulating cachexia biomarkers, and molecular markers of muscle atrophy and adipose tissue wasting are shown. We correlate inflammatory markers and body weight dependent on age in patients with cancer. Results: We note fundamental differences between mouse strains. Aging aggravates weight loss in LLC-injected C57BL/6J mice, drives it in C57BL/6N mice, and does not influence weight loss in C26-injected BALB/c mice. Glucose tolerance is unchanged in cachectic young and old mice. The stress marker GDF15 is elevated in cachectic BALB/c mice independent of age and increased in old C57BL/6N and J mice. Inflammatory markers correlate significantly with weight loss only in young mice and patients. Conclusions: Aging affects cachexia development and progression in mice in a strain-dependent manner and influences the inflammatory profile in both mice and patients. Age is an important factor to consider for future cachexia studies.

20 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MBMaike Becker
Maike Becker
SKStefanie Kälin
Stefanie Kälin
ANAnne H. Neubig
Anne H. Neubig
MLMichael Lauber
Michael Lauber
DODaria Opaleva
Daria Opaleva
CDCarolin Daniel
Carolin Daniel
The hypothalamus in the central nervous system (CNS) has important functions in controlling systemic metabolism. A calorie-rich diet triggers CNS immune activation, impairing metabolic control and promoting obesity and Type 2 Diabetes (T2D), but the mechanisms driving hypothalamic immune activation remain unclear. Here we identify regulatory T cells (Tregs) as key modulators of hypothalamic immune responses. In mice, calorie-rich environments activate hypothalamic CD4 + T cells, infiltrating macrophages and microglia while reducing hypothalamic Tregs. mRNA profiling of hypothalamic CD4 + T cells reveals a Th1-like activation state, with increased Tbx21 , Cxcr3 and Cd226 but decreased Ccr7 and S1pr1 . Importantly, results from Treg loss-of function and gain-of-function experiments show that Tregs limit hypothalamic immune activation and reverse metabolic impairments induced by hyper-caloric feeding. Our findings thus help refine the current model of Treg-centered immune-metabolic crosstalk in the brain and may contribute to the development of precision immune modulation for obesity and diabetes.

18 May 2026 in Nature Communications
Verified
Journal Article
Open access
MBMaike Becker
Maike Becker
SKStefanie Kälin
Stefanie Kälin
ANAnne H. Neubig
Anne H. Neubig
MLMichael Lauber
Michael Lauber
DODaria Opaleva
Daria Opaleva
CDCarolin Daniel
Carolin Daniel